Meten van de geactiveerde stollingstijd tijdens slagaderlijke vaatingrepen.

Aim of the MANCO study is to establish for once and for all that monitoring the effect of heparin during Non-Cardiac Vascular interventions is essential to ensure the individual patient of safe and tailor-made anticoagulation. Not measuring the effect of the administered heparin exposes the patient to unnecessary risks of thrombo-embolic and bleeding complications. First aim of the MANCO study is to prove that the standardized bolus of 5000 IU of heparin, used by 90% of vascular specialists in Europe, results in inadequate anticoagulation in more than 80% of patients ACT less than 250 seconds). These measurements will be performed using the Hemostasis Management System by Medtronic. The calculated heparin dose using the HMS will be evaluated to test its predictive value to ensure every patient of tailor-made anticoagulation, thereby reducing the avoidable risks of thrombo-embolic and bleeding complications.

Aim of the MANCO study is to establish for once and for all that monitoring the effect of heparin during NCVI is essential to ensure the individual patient of safe and tailor-made anticoagulation. Not measuring the effect of the administered heparin exposes the patient to unnecessary risks of thrombo-embolic and bleeding complications. First aim of the MANCO study is to prove that the standardized bolus of 5000 IU of heparin, used by 90% of vascular specialists in Europe, results in inadequate anticoagulation in more than 80% of patients. These measurements will be performed using the Hemostasis Management System by Medtronic„µ. The calculated heparin dose using the HMS will ensure every patient of tailor-made anticoagulation, thereby reducing the avoidable risks of thrombo-embolic and bleeding complications.

30 days after intervention or same admission; 6 weeks; 6 months; 12 months

To evaluate if the current practice of using a standardized bolus of 5000 IU of heparin during NCVI causes adequate periprocedural anticoagulation in the individual patient. This evaluation will be performed using the HMS. The calculated heparin dose response curve will be evaluated on the desired value of the ACT of 250 seconds. All participating centers and vascular surgeons and/or IR are allowed to apply their local heparin protocols.